{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-002694","form_type":"8-K","ticker":"NXTC","cik":"0001661059","company_name":"NextCure, Inc.","filed_at":"2023-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.047007+00:00","generated_at":"2026-06-18T15:30:18.620290+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"NextCure reports FY2022 net loss of $74.7M; cash $159.9M, runway into mid-2025","bullets":["Net loss of $74.7M for FY2022 vs $69.4M in FY2021, driven by higher R&D expenses.","Cash, equivalents, and marketable securities $159.9M at Dec 31, 2022, down from $219.6M.","R&D expenses $54.2M (FY2022) vs $50.2M (FY2021); G&A $21.7M vs $20.6M.","NC410 Phase 1b/2 combo with pembrolizumab update expected mid-2023; NC762 update Q4 2023.","NC525 dosed first patient in Phase 1 AML trial Feb 2023; initial data expected Q4 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-002694","json":"https://secwatch.observer/filing/0001558370-23-002694.json","markdown":"https://secwatch.observer/filing/0001558370-23-002694.md","text":"https://secwatch.observer/filing/0001558370-23-002694.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661059/000155837023002694/0001558370-23-002694-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661059/000155837023002694/nxtc-20230302x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T15:30:18.620290+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}